Thank you to our partner Astellas for their support in producing this podcast episode.

Claudin-18.2 (CLDN18.2) represents an important emerging biomarker in gastrointestinal cancer.

In this episode of The Pathology Report, host Dr Donna Lenghaus is joined by Professor Beena Kumar and A/Professor Katrin Sjoquist to discuss the evolving role of biomarkers in the management of gastric carcinoma, and how CLDN18.2 testing can help identify patients who may benefit from targeted therapies.

Key topics discussed include:

• How improved understanding of tumour biology and identification of biomarkers is changing the management of gastrointestinal cancers.
• The clinical utility of using CLDN18.2 testing to facilitate targeted therapies for eligible patients, including Zolbetuximab.
• Pathology considerations, including appropriate biopsy, controls, specimen age, tumour location, scoring and reporting standards.
• The role of the multidisciplinary team.
• Resources and other emerging biomarkers.

In exploring the use of CLDN18.2 as a predicative biomarker, this episode highlights that accurate immunohistochemistry testing, adequate tissue, standardised reporting and strong communication between pathology and clinical teams is essential to ensuring eligible patients can access targeted treatments.

RCPA members

This podcast is an RCPA-endorsed CPD activity. Each episode gives you an opportunity to gain CPD hours in three easy steps:

Step 1. Listen or watch the podcast here, on your favourite podcast channel or on YouTube

Step 2. To claim your CPD hours, please complete and pass this short online quiz

Step 3. Sit back and let us load your CPD hours into your CPD profile for you.

Did you enjoy this episode? Make sure you subscribe to The Pathology Report so you know when the next episode drops, and consider leaving us a five-star review so more people can discover the podcast.

The Pathology Report is produced by the Royal College of Pathologists of Australasia and is part of the Talking HealthTech Podcast Network.

Learn more about the RCPA at rcpa.edu.au and discover other shows in the network at talkinghealthtech.com/podcast/network.

What are the current trends and operational realities in the genetic diagnosis of inherited cardiovascular diseases?

In this episode of The Pathology Report, host A/Prof Caitlin Keighley is joined by A/Prof Jodie Ingles from the Royal Prince Alfred Hospital to discuss the impact of next-generation sequencing (NGS) on the diagnosis of inherited cardiovascular diseases, and how better to care for families.

Using real-world examples, topics explored in this episode include:

• The role of a genetic counsellor.
• Genetic testing and diagnostic yield in unsolved cases.
• Expanding knowledge through ongoing research.
• Current barriers affecting access to genetic services.
• Importance of collaboration, postmortem testing and advocacy.

By highlighting key priorities moving forward, this episode provides insights into how NGS can be best utilised to support families impacted by inherited cardiovascular disease, ensuring they receive the answers they need in a timely manner.

RCPA members

This podcast is an RCPA-endorsed CPD activity. Each episode gives you an opportunity to gain CPD hours in three easy steps:

Step 1. Listen or watch the podcast here, on your favourite podcast channel or on YouTube

Step 2. To claim your CPD hours, please complete and pass this short online quiz

Step 3. Sit back and let us load your CPD hours into your CPD profile for you.

Did you enjoy this episode? Make sure you subscribe to The Pathology Report so you know when the next episode drops, and consider leaving us a five-star review so more people can discover the podcast.

The Pathology Report is produced by the Royal College of Pathologists of Australasia and is part of the Talking HealthTech Podcast Network.

Learn more about the RCPA at rcpa.edu.au and discover other shows in the network at talkinghealthtech.com/podcast/network.

Thank you to our partner Roche for their support in producing this podcast episode.

How can multidisciplinary teams (MDTs) improve cancer care, and make the most of greater pathology input, molecular testing and emerging technologies?

In this episode of The Pathology Report, host Dr Ben Dessauvagie is joined by pathologists Prof Gelareh Farshid and and oncologist, A/Prof Jenny Lee, to explore the role of these collaborative forums where pathology, radiology and clinical information are integrated to guide patient management.

The key topics discussed include:

• the educational value of MDTs
• the importance of clinical history on request forms
• how pathologists contribute to MDTs
• the benefits and drawbacks of virtual meetings
• ongoing challenges, potential solutions as well as future opportunities.

The panel highlights the importance of open communication, mutual respect and active participation in ensuring that MDTs are effective and support shared clinical decision making.

RCPA members

This podcast is an RCPA-endorsed CPD activity. Each episode gives you an opportunity to gain CPD hours in three easy steps:

Step 1. Listen or watch the podcast here, on your favourite podcast channel or on YouTube

Step 2. To claim your CPD hours, please complete and pass this short online quiz

Step 3. Sit back and let us load your CPD hours into your CPD profile for you.

Did you enjoy this episode? Make sure you subscribe to The Pathology Report so you know when the next episode drops, and consider leaving us a five-star review so more people can discover the podcast.

The Pathology Report is produced by the Royal College of Pathologists of Australasia and is part of the Talking HealthTech Podcast Network.

Learn more about the RCPA at rcpa.edu.au and discover other shows in the network at talkinghealthtech.com/podcast/network.